RHINOCORT ALLERGY SPRAY OTC
Generic Name and Formulations:
Budesonide 32mcg; per nasal spray; scent- and alcohol-free.
McNeil Consumer Healthcare
Indications for RHINOCORT ALLERGY SPRAY:
To relieve symptoms of seasonal or perennial allergic rhinitis.
Adults and Children:
<6yrs: not recommended. 6–<12yrs: initially 1 spray in each nostril once daily; increase to 2 sprays per nostril once daily if no improvement; reduce to 1 spray in each nostril once daily when symptoms improve. ≥12yrs: use 2 sprays per nostril once daily; reduce to 1 spray in each nostril once daily when symptoms improve.
Do not use for treating the common cold or use more than recommended. Avoid eyes or mouth. Recent nose ulcers or surgery. Nose injury that has not healed. Eye infection. Glaucoma. Cataracts. Re-evaluate if no improvement after 2 weeks. Discontinue if exposed to chickenpox, measles, or tuberculosis, have symptoms of an infection (eg, persistent fever), change in vision, severe or frequent nosebleeds. Children 6–<12yrs: monitor and re-evaluate if treatment requires >2 months per year. Pregnancy. Nursing mothers.
Concomitant other steroid drugs for asthma, allergies, or skin rash.
Reduced growth velocity in children.
Spray—5mL (60 sprays), 8.4mL (120 sprays)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|